Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent ...

Malvern, Pennsylvania Tuesday, July 22, 2025, 17:00 Hrs [IST] ...

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

OncoZenge AB ("OncoZenge" or "the Company") today announced it has engaged Meribel Pharma Solutions ("Meribel," formerly Recipharm) as its Contract Development and Manufacturing Organization (CDMO) fo ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...